Copley v. Bactolac Pharmaceutical, Inc.

CourtDistrict Court, E.D. New York
DecidedMarch 13, 2023
Docket2:18-cv-00575
StatusUnknown

This text of Copley v. Bactolac Pharmaceutical, Inc. (Copley v. Bactolac Pharmaceutical, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Copley v. Bactolac Pharmaceutical, Inc., (E.D.N.Y. 2023).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK -----------------------------------------------x CHARLES COPLEY, et al., Individually and on behalf of all others s imilarly situated,

Plaintiffs,

-against-

MEMORANDUM AND ORDER BACTOLAC PHARMACEUTICAL,

INC., et al., Case No. 2:18-CV-00575-FB-PK

Case No. 2:20-CV-01338-FB-PK Defendants. ------------------------------------------------x JEFFREY FARIS, et al., Individually and on behalf of all others s imilarly situated,

BACTOLAC PHARMACEUTICAL, INC., et al.,

Defendants. ------------------------------------------------x Appearances: For the Plaintiffs: For Defendant Bactolac: JAMES J. BILSBORROW ANDREW PHILIP KATES Weitz & Luxenberg, PC CHRISTIAN H. GANNON 700 Broadway JANINE J. WONG New York, NY 10003 JOEL MERCHANT MATTHEW D. KELLY PETER SAMBERG Segal McCambridge Singer & Weitz & Luxenberg, PC Mahoney 100 Ardsley Avenue West 850 Third Avenue, Suite 1100 Ardsley on Hudson, NY 10503 New York, NY 10022 I nterested Party: CAMERON W. BROWN BREON PEACE Stackpole and French Law Office United States Attorney’s Office 225 Maple Street By: MELANIE M. SPEIGHT Stowe, VT 05672 Eastern District of New York 271A Cadman Plaza East HOWARD A. FRIED B rooklyn, NY 11201 McGivney Kluger Clark & Intoccia, P.C. 80 Broad Street, 23rd Floor New York, NY 10004

For Defendant NaturMed: KAREN CAMPBELL Lewis Brisbois 77 Water Street, 21st Floor New York, NY 10005

SHEILA CARMODY COURTNEY HENSON JENNIFER HADLEY CATERO Snell and Wilmer L.L.P. 400 East Van Buren Street Suite 1900 Phoenix, AZ 85004

JOHN A. ANSELMO Tyson & Mendes 4 20 Lexington Avenue, Suite 2800 New York, NY 10017

For Defendant Independent Vital Life: ANTHONY AUSTIN JUSTIN R. DEPAUL 2394 E. Camelback Road Suite 600 Phoenix, AZ 85016

JOSEPH J. ORTEGO MARISSA A. MUSCARELLA MATTHEW FORZANO SANTO BARRUSO Nixon Peabody LLP 275 Broadhollow Road, Suite 300 Melville, NY 11747 BLOCK, Senior District Judge: This putative multi-state class action stems from harm allegedly suffered by

plaintiffs who purchased and consumed All Day Energy Greens (“ADEG”), a dietary supplement that they claim caused them to become ill. After years of litigation and settlement negotiations aided by a mediator, the parties have reached

a proposed class settlement (the “Settlement”). Now, the parties seek the Court’s final approval of that Settlement. For the reasons that follow, plaintiffs’ motion to approve the Settlement is granted in all respects except as to proposed attorneys’ fees.

I. OVERVIEW The Court granted preliminary approval of the Settlement on January 10, 2022. The Settlement dictates that eligible class members who opt in may elect to

receive either (i) a coupon worth $10 toward the future purchase of any of the Defendants’ products, redeemable for a period of three years, or (ii) a cash payment, which is projected to be approximately $15.85. Separately, the class representatives are to receive service awards of $5,000 each. Class counsel have

also moved for a payout of $1,194,657.34 in attorneys’ fees and costs. Through the Department of Justice’s (“DOJ”) Consumer Protection Branch and the United States Attorney’s Office for the Eastern District of New York

(E.D.N.Y.), the United States (the “U.S.”) has objected to the Settlement. It argues that it is unfair for two reasons: (i) because it primarily benefits class counsel instead of class members, and (ii) because the representatives of the class will

receive disproportionate awards compared to the rest of the class members. In the analysis that follows, the Court lays out its findings that the Settlement, including the service awards, is procedurally and substantively fair and

reasonable in accordance with Rule 23(e)(2). However, the Court rejects the proposed attorneys’ fee award. II. FACTS AND PROCEDURAL HISTORY Defendants are NaturMed, Inc. d/b/a Institute for Vibrant Living

(“NaturMed”), the company that designed, marketed, distributed and sold ADEG, Independent Vital Life, LLC (“IVL”), the alleged successor-in-interest of NaturMed, and Bactolac Pharmaceutical, Inc. (“Bactolac”), the company that

blended and packaged ADEG pursuant to its contract with NaturMed (collectively, the “Defendants”). The class representatives (“Class Representatives”)1 brought suit individually and on behalf of all others similarly situated (collectively,

1 The Class Representatives are the named plaintiffs: Charles Copley, Jason Evans, Humberto Garcia, Luz Angelina Garcia, Joan McDonald, John Peterson, Natalie Roberts, Donald Skare, individually and as personal representative for Betty Skare, David Stone, Kaye Wink, individually and as next of kin of Donald Wink, Jeffrey Faris, Antonia Hampton, Raul Robles, and Kathleen Cannon. On July 13, 2020, the Court granted a consent motion to consolidate Faris v. Bactolac Pharmaceutical, Inc., No. 20-CV-1338 (FB)(PK) with this case. The Class Representatives include the named plaintiffs from both cases. “Plaintiffs”) alleging that Defendants engaged in false, misleading, and deceptive marketing of ADEG. According to Plaintiffs, Defendants’ representations of

ADEG as an all-natural product that would naturally increase energy and support digestion were “a sham.” Am. Compl. ¶ 2. In addition, Plaintiffs allege that ADEG “consisted of a dangerous mixture that resulted in serious illness and/or death

among those who consumed it.” Id. Plaintiffs claim that in 2014, NaturMed became aware that ADEG was making customers sick with gastrointestinal distress. After these reports surfaced, NaturMed inquired with Bactolac about possible contamination of the product.

When Bactolac did not cooperate fully with NaturMed’s request for information, NaturMed switched to a new manufacturer in July 2015. In March 2016, Defendants recalled ADEG canisters that were sold during a specified period from

2014 to 2016. Plaintiffs contend that Defendants failed to timely warn consumers of the products’ harmful effects and issue a timely recall. Plaintiffs also find fault with the 2016 recall, alleging that NaturMed attempted to downplay the potential for danger posed by its product, which contained ingredients that were not on the

label. The Class Representatives are purchasers of canisters of ADEG from the recalled lot who allegedly became ill after consuming the product, some so seriously that they required hospitalization. The class that they seek to represent is made up of purchasers of ADEG from the 2016 recalled lot.

In 2017, IVL purchased NaturMed after the company fell into financial distress, apparently because of the recall and personal injury and wrongful death lawsuits stemming from the contaminated product, as well as a defaulted-upon

loan from its secured lender. Plaintiffs allege that IVL is the “same legal person” as NaturMed. Am Compl. ¶ 29. On January 26, 2018, Plaintiffs filed this action asserting numerous claims stemming from the aforementioned harm. Roughly six months later, Plaintiffs

amended their complaint, and NaturMed answered with crossclaims against Bactolac. In Plaintiffs’ Amended Complaint, they alleged claims on behalf of a nationwide class, which is defined as individuals who purchased canisters of

ADEG from July 1, 2014 to the present that were manufactured and/or blended by Bactolac between January 1, 2014 and December 31, 2015. Plaintiffs also have initiated comparable statewide claims in ten states.2 The Court has jurisdiction over those claims under the Class Action Fairness Act (“CAFA”). 28 U.S.C. § 1332(d).

After discovery, Bactolac moved to dismiss the Plaintiffs’ claims and for judgment on the pleadings with respect to NaturMed’s crossclaims, as well as to

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re: Painewebber Limited Partnerships Litigation
147 F.3d 132 (Second Circuit, 1998)
Savoie v. Merchants Bank
166 F.3d 456 (Second Circuit, 1999)
Blessing v. Sirius Xm Radio Inc.
507 F. App'x 1 (Second Circuit, 2012)
Nicklos Ciolino v. Theodore Frank
716 F.3d 1173 (Ninth Circuit, 2013)
McReynolds v. Richards-Cantave
588 F.3d 790 (Second Circuit, 2009)
Roberts v. Texaco, Inc.
979 F. Supp. 185 (S.D. New York, 1997)
Sylvester v. Cigna Corp.
369 F. Supp. 2d 34 (D. Maine, 2005)
In Re Initial Public Offering Securities Litigation
671 F. Supp. 2d 467 (S.D. New York, 2009)
Figueroa v. Sharper Image Corp.
517 F. Supp. 2d 1292 (S.D. Florida, 2007)
John Galloway v. The Kansas City Landsmen, LLC
833 F.3d 969 (Eighth Circuit, 2016)
Josue Romero v. Provide Commerce, Inc.
906 F.3d 747 (Ninth Circuit, 2018)
Vicki Linneman v. Vita-Mix Corp.
970 F.3d 621 (Sixth Circuit, 2020)
Steve Chambers v. Whirlpool Corp.
980 F.3d 645 (Ninth Circuit, 2020)
Goldberger v. Integrated Resources, Inc.
209 F.3d 43 (Second Circuit, 2000)
Berkson v. Gogo LLC
147 F. Supp. 3d 123 (E.D. New York, 2015)
Wal-Mart Stores, Inc. v. Visa U.S.A. Inc.
396 F.3d 96 (Second Circuit, 2005)
Levitt v. Southwest Airlines Co.
799 F.3d 701 (Seventh Circuit, 2015)
In re Sumitomo Copper Litigation
189 F.R.D. 274 (S.D. New York, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
Copley v. Bactolac Pharmaceutical, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/copley-v-bactolac-pharmaceutical-inc-nyed-2023.